Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

被引：0

作者：

Gonzalez, Carmen ^{[1
]}

Simoes, Catia ^{[1
]}

Burgos, Leire ^{[1
]}

Martinez-Cuadron, David ^{[2
]}

Sarvide, Sarai ^{[1
]}

Alignani, Diego ^{[1
]}

Lopez, Aitziber ^{[1
]}

Gui, Yujuan ^{[3
]}

Komic, Hana ^{[4
]}

Schmachtel, Tessa ^{[5
]}

Botella, Carmen ^{[6
]}

Boyero, Raimundo Garcia ^{[7
]}

Santaolla, Esther Perez ^{[8
]}

Gil, Cristina ^{[9
]}

Algarra, Jesus Lorenzo ^{[10
]}

Lloris, Maria Jose Sayas ^{[11
]}

Ibanez, Francisco ^{[12
]}

Torres, Laura ^{[13
]}

Cano-Ferri, Isabel

Acuna-Cruz, Evelyn ^{[13
]}

Arce, Olga ^{[14
]}

Thoren, Fredrik B. ^{[4
]}

Rieger, Michael A. ^{[5
]}

San-Miguel, Jesus F. ^{[1
]}

Prosper, Felipe ^{[1
]}

Montesinos, Pau ^{[2
]}

Paiva, Bruno ^{[1
]}

机构：

[1] Univ Navarra, Ctr Invest Med Aplicada, CCUN, IDISNA,CIBER ONC,Clin Univ Navarra, Pamplona, Spain

[2] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

[3] BD Biosci, Single Cell Multi, Vianen, Netherlands

[4] Univ Gothenburg, Inst Biomed, TIMM Lab, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden

[5] Goethe Univ Frankfurt, Dept Med Hematol Oncol 2, Frankfurt, Germany

[6] Hosp Gen Univ Alicante, Dept Hematol, Alicante, Spain

[7] Hosp Gen Univ Castellon, Castellon de La Plana, Spain

[8] Mendaro Hosp, Donostia San Sebastian, Spain

[9] Hosp Gen Univ Alicante, Alicante, Spain

[10] Hosp Gen Albacete, Albacete, Spain

[11] Hosp Dr Peset, Valencia, Spain

[12] Hosp Gen Univ Valencia, Valencia, Spain

[13] Hosp Univ & Politecn La Fe, Valencia, Spain

[14] Hosp Univ Basurto, Bilbao, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-203076

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4328 / 4329

页数：2

共 50 条

[31] Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
Das, Nupur
Gupta, Ritu
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2023, 44 (05) : 515 - 524
[32] Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
Ganzel, Chezi
Sun, Zhuoxin
Baslan, Timour
Zhang, Yanming
Gonen, Mithat
Abdel-Wahab, Omar, I
Racevskis, Janis
Garrett-Bakelman, Francine
Lowe, Scott W.
Fernandez, Hugo F.
Ketterling, Rhett
Luger, Selina M.
Litzow, Mark
Lazarus, Hillard M.
Rowe, Jacob M.
Tallman, Martin S.
Levine, Ross L.
Paietta, Elisabeth
LEUKEMIA RESEARCH, 2022, 123
[33] Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel
Duchstein, Lara
Sloane, Hillary S.
Fredebohm, Johannes
Ryder, Matthew
BLOOD, 2020, 136
[34] Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?
Hochman, Michael Jamie
Othus, Megan
Shaw, Carole
Gardner, Kelda
Percival, Mary-Elizabeth M.
Hendrie, Paul C.
Estey, Elihu
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Pre-Transplant Levels of Multiparametric Flow-Cytometry Measurable Residual Disease (MFC-MRD) Predict Outcomes in Children with Acute Myeloid Leukemia Given Allogeneic Hematopoietic Stem Cell Transplantation
Buldini, Barbara
Merli, Pietro
Varotto, Elena
Masetti, Riccardo
Gabelli, Maria
Zecca, Marco
Fagioli, Franca
Scarparo, Pamela
Algeri, Mattia
Biffi, Alessandra
Pigazzi, Martina
Pagliara, Daria
Locatelli, Franco
BLOOD, 2023, 142
[36] Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
Patkar, Nikhil
Kakirde, Chinmayee
Shaikh, Anam Fatima
Salve, Rakhi
Bhanshe, Prasanna
Chatterjee, Gaurav
Rajpal, Sweta
Joshi, Swapnali
Chaudhary, Shruti
Kodgule, Rohan
Ghoghale, Sitaram
Deshpande, Nilesh
Shetty, Dhanalaxmi
Khizer, Syed Hasan
Jain, Hasmukh
Bagal, Bhausaheb
Menon, Hari
Khattry, Navin
Sengar, Manju
Tembhare, Prashant
Subramanian, Papagudi
Gujral, Sumeet
LEUKEMIA, 2021, 35 (05) : 1392 - 1404
[37] Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
Nikhil Patkar
Chinmayee Kakirde
Anam Fatima Shaikh
Rakhi Salve
Prasanna Bhanshe
Gaurav Chatterjee
Sweta Rajpal
Swapnali Joshi
Shruti Chaudhary
Rohan Kodgule
Sitaram Ghoghale
Nilesh Deshpande
Dhanalaxmi Shetty
Syed Hasan Khizer
Hasmukh Jain
Bhausaheb Bagal
Hari Menon
Navin Khattry
Manju Sengar
Prashant Tembhare
Papagudi Subramanian
Sumeet Gujral
Leukemia, 2021, 35 : 1392 - 1404
[38] Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
Dix, Caroline
Lo, Tsun-Ho
Clark, Georgina
Abadir, Edward
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 14
[39] MULTIPARAMETER FLOW-CYTOMETRY (MFC) MONITORS RESIDUAL DISEASE (RD) DURING COMPLETE REMISSION (CR) OF ACUTE MYELOID-LEUKEMIA (AML)
BAER, MR
LO, CH
MEANS, J
SALZMAN, G
FRANKEL, SR
LAWRENCE, D
MOORE, JO
HERZIG, GP
SCHIFFER, CA
BLOOMFIELD, CD
STEWART, CC
BLOOD, 1994, 84 (10) : A307 - A307
[40] A Multiomic, Single-Cell Measurable Residual Disease (scMRD) Assay for Simultaneous Assessment of DNA Mutations and Surface Immunophenotypes in Acute Myeloid Leukemia
Thompson, Kathryn
Geller, Benjamin
Nousheen, Lubna
Krishnan, Indira
Wang, Shu
Mendoza, Daniel
Druley, Todd E.
Sciambi, Adam
BLOOD, 2024, 144 : 6168 - 6168

← 1 2 3 4 5 →